In this study, a mechanism in which low-dose hyper-radiosensitivity (HRS) is permanently removed, induced by low-dose-rate (LDR) (0.2–0.3 Gy/h for 1 h) but not by high-dose-rate priming (0.3 Gy at 40 Gy/h) was investigated. One HRS-negative cell line (NHIK 3025) and two HRS-positive cell lines (T-47D, T98G) were used. The effects of different pretreatments on HRS were investigated using the colony assay. Cell-based ELISA was used to measure nitric oxide synthase (NOS) levels, and microarray analysis to compare gene expression in primed and unprimed cells. The data show how permanent removal of HRS, previously found to be induced by LDR priming irradiation, can also be induced by addition of nitric oxide (NO)-donor DEANO combined with either high-dose-rate priming or exposure to prolonged cycling hypoxia followed by reoxygenation, a treatment not involving radiation. The removal of HRS appears not to involve DNA damage induced during priming irradiation as it was also induced by LDR irradiation of cell-conditioned medium without cells present. The permanent removal of HRS in LDR-primed cells was reversed by treatment with inducible nitric oxide synthase (iNOS) inhibitor 1400W. Furthermore, 1400W could also induce HRS in an HRS-negative cell line. The data suggest that LDR irradiation for 1 h, but not 15 min, activates iNOS, and also that sustained iNOS activation is necessary for the permanent removal of HRS by LDR priming. The data indicate that nitric oxide production is involved in the regulatory processes determining cellular responses to low-dose-rate irradiation.

Irradiation of T-47D cells with 0.3 Gy delivered by a (60)Co source at a low dose rate of 0.3 Gy/h abolished low-dose hyper-radiosensitivity (HRS) for at least 14 months (with continuous cell culturing), while the same dose administered acutely (40 Gy/h) eliminated HRS for less than 24 h. Medium transferred from the low-dose-rate primed cells (low-dose-rate ICCM) to unirradiated cells eliminated HRS in recipient cells even if the donor cells had been cultivated for 14 months after the priming dose. Thus low-dose-rate priming activates mechanisms that involve modification or induction of a factor in the medium. This factor affects unirradiated cells in such a way that HRS is eliminated in cells exposed to medium from the primed cells. However, only cells directly exposed to low-dose-rate radiation induce or modify the putative factor, since unirradiated cells that were exposed to low-dose-rate ICCM regained HRS within 2 weeks of cultivation in fresh medium. The ability of ICCM to eliminate HRS in recipient cells is dependent on dose rate. However, an increase in clonogenic survival was observed in cells receiving only medium transfer without subsequent irradiation that was independent of dose rate.

Hypoxia is an important and common characteristic of many human tumors. It is a challenge clinically due to the correlation with poor prognosis and resistance to radiation and chemotherapy. Understanding the biochemical response to hypoxia would facilitate the development of novel therapeutics for cancer treatment. Here, we investigate alterations in gene expression in response to hypoxia by quantitative proteome analysis using stable isotope labeling with amino acids in cell culture (SILAC) in conjunction with LCMS/MS. Human HeLa cells were kept either in a hypoxic environment or under normoxic conditions. 125 proteins were found to be regulated, with maximum alteration of 18-fold. In particular, three clusters of differentially regulated proteins were identified, showing significant upregulation of glycolysis and downregulation of mitochondrial ribosomal proteins and translocases. This interaction is likely orchestrated by HIF-1. We also investigated the effect of hypoxia on the cell cycle, which shows accumulation in G1 and a prolonged S phase under these conditions. Implications. This work not only improves our understanding of the response to hypoxia, but also reveals proteins important for malignant progression, which may be targeted in future therapies.

T-47D human breast cancer cells were irradiated with 60 Co γ-radiation and radiation response was measured by loss of ability of single-cells to form colonies. The influence of the dose-rate on the ability of priming irradiation to abolish Low-Dose Hyper-Radiosensitivity (LDHRS) was investigated. In agreement with previous reports, the LDHRS was abolished by an acute priming dose of 0.3 Gy given 6 h prior to the challenge dose. When the interval between the priming-and challenge-doses was increased to 24 h, LDHRS was restored. However, when the priming dose was delivered at a low dose-rate (0.3 Gy/h), the abolition of LDHRS that again appeared 6 h following the priming dose, now persisted for intervals of up to 14 weeks between doses even after 28 passages during the 14 weeks. . (2007) 'Recovery of low-dose hyper-radiosensitivity following a small priming dose depends on priming dose-rate', Int.

Immunotherapy is a growing field in cancer research. A privileged tumor-associated antigen that has received much attention is N-glycolyl (NeuGc) GM3. This ganglioside is present in several types of cancer, but is almost undetectable in human healthy tissues. However, its non-hydroxylated variant, NeuAc GM3, is abundant in all mammals. Due to a deletion in the human gene encoding the key enzyme for synthesis of NeuGc, humans, in contrast to other mammals, cannot synthesize NeuGc GM3. Therefore the presence of this ganglioside in human cancer cells represents an enigma. It has been shown that hypoxic conditions trigger the expression of NeuGc gangliosides, which not only serve as attractive targets for cancer therapy, but also as diagnostic and prognostic tumor marker. Here, we confirm hypoxia-induced expression of the NeuGc GM3 ganglioside also in HeLa cells and reveal several candidate proteins, in particular GM3 synthase and subunit B of respiratory complex II (SDHB), that may be involved in the generation of NeuGc GM3 by SILAC-based proteome analysis. These findings have the potential to significantly advance our understanding of how this enigmatic tumor-associated antigen is produced in humans, and also suggest a possible mechanism of action of anti-tumor antibodies that recognize hypoxia markers, such as 14F7.